1. Malik V. S., Willet W. C., Hu F. B. Nearly a decade on- trends, risk factors and policy implications in global obesity. Nature Reviews Endocrinology. 2020;16(11):615–616. doi:10.1038/s41574-020-00411-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Wang J. Y., Wang Q.-W., Yang X.-Y., et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Frontiers in Endocrinology. 2023;14 doi:10.3389/fendo.2023.1085799.1085799 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Guh D. P., Zhang W., Bansback N., Amarsi Z., Birmingham C. L., Anis A. H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):p. 88. doi:10.1186/1471-2458-9-88. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Lopez-Jimenez F., Almahmeed W., Bays H., et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. European Journal of Preventive Cardiology. 2022;29(17):2218–2237. doi:10.1093/eurjpc/zwac187. [PubMed] [CrossRef] [Google Scholar]
5. Klop B., Elte J. W. F., Cabezas M. C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–1240. doi:10.3390/nu5041218. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Blüher M. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology. 2019;15(5):288–298. doi:10.1038/s41574-019-0176-8. [PubMed] [CrossRef] [Google Scholar]
7. Haase C. L., Lopes S., Olsen A. H., Satylganova A., Schnecke V., McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. International Journal of Obesity. 2021;45(6):1249–1258. doi:10.1038/s41366-021-00788-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Wing R. R., Lang W., Wadden T. A., et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486. doi:10.2337/dc10-2415. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Ma C., Avenell A., Bolland M., et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ. 2017;359:p. j4849. doi:10.1136/bmj.j4849. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Cooper T. C., Simmons E. B., Webb K., Burns J. L., Kushner R. F. Trends in weight regain following roux-en-Y gastric bypass (RYGB) bariatric surgery. Obesity Surgery. 2015;25(8):1474–1481. doi:10.1007/s11695-014-1560-z. [PubMed] [CrossRef] [Google Scholar]
11. Koufakis T., Kotsa K., Papanas N. Remission of type 2 diabetes depends on prompt comprehensive lifestyle changes upon diagnosis: how can this “Road to Damascus” experience be supported? Journal of Integrative Medicine. 2022;20(4):288–291. doi:10.1016/j.joim.2022.04.001. [PubMed] [CrossRef] [Google Scholar]
12. Folli F., Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opinion on Investigational Drugs. 2011;20(12):1717–1722. doi:10.1517/13543784.2011.630660. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Jackson V. M., Breen D. M., Fortin J. P., et al. Latest approaches for the treatment of obesity. Expert Opinion on Drug Discovery. 2015;10(8):825–839. doi:10.1517/17460441.2015.1044966. [PubMed] [CrossRef] [Google Scholar]
14. Nauck M. A., Heimesaat M. M., Behle K., et al. Effects of glucagon‐like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical Endocrinology and Metabolism. 2002;87(3):1239–1246. doi:10.1210/jcem.87.3.8355. [PubMed] [CrossRef] [Google Scholar]
15. Meier J. J. GLP‐1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012;8(12):728–742. doi:10.1038/nrendo.2012.140. [PubMed] [CrossRef] [Google Scholar]
16. Karagiannis T., Bekiari E., Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023;66(10):1859–1868. doi:10.1007/s00125-023-05962-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Caro R., Samsel D., Savel P. Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment? Evidence-Based Practice. 2023;26(5):7–8. doi:10.1097/ebp.0000000000001786. [CrossRef] [Google Scholar]
18. Tian E., Sun G., Sun G., et al. Small-molecule-based lineage reprogramming creates functional astrocytes. Cell Reports. 2016;16(3):781–792. doi:10.1016/j.celrep.2016.06.042. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Minkel H. R., Anwer T. Z., Arps K. M., Brenner M., Olsen M. L. Elevated GFAP induces astrocyte dysfunction in caudal brain regions: a potential mechanism for hindbrain involved symptoms in type II Alexander disease. Glia. 2015;63(12):2285–2297. doi:10.1002/glia.22893. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Drucker D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001. [PubMed] [CrossRef] [Google Scholar]
21. Ard J., Fitch A., Fruh S., Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Advances in Therapy. 2021;38(6):2821–2839. doi:10.1007/s12325-021-01710-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Nogueiras R., Pérez-Tilve D., Veyrat-Durebex C., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. Journal of Neuroscience. 2009;29(18):5916–5925. doi:10.1523/JNEUROSCI.5977-08.2009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. van Can J., Sloth B., Jensen C. B., Flint A., Blaak E. E., Saris W. H. M. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014;38(6):784–793. doi:10.1038/ijo.2013.162. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Gaykema R. P., Newmyer B. A., Ottolini M., et al. Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. Journal of Clinical Investigation. 2017;127(3):1031–1045. doi:10.1172/JCI81335. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Wang X.-F., Liu J.-J., Xia J., Liu J., Mirabella V., Pang Z. P. Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons. Cell Reports. 2015;12(5):726–733. doi:10.1016/j.celrep.2015.06.062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Liu J., Conde K., Zhang P., et al. Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus. Neuron. 2017;96(4):897–909.e5. doi:10.1016/j.neuron.2017.09.042. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Williams E. K., Chang R. B., Strochlic D. E., Umans B. D., Lowell B. B., Liberles S. D. Sensory neurons that detect stretch and nutrients in the digestive system. Cell. 2016;166(1):209–221. doi:10.1016/j.cell.2016.05.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Iwasaki Y., Sendo M., Dezaki K., et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. 2018;9(1):p. 113. doi:10.1038/s41467-017-02488-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Krieger J. P., Arnold M., Pettersen K. G., Lossel P., Langhans W., Lee S. J. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65(1):34–43. doi:10.2337/db15-0973. [PubMed] [CrossRef] [Google Scholar]
30. Sisley S., Gutierrez-Aguilar R., Scott M., D’Alessio D. A., Sandoval D. A., Seeley R. J. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. Journal of Clinical Investigation. 2014;124(6):2456–2463. doi:10.1172/JCI72434. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Furness J. B., Koopmans H. S., Robbins H. L., Clerc N., Tobin J. M., Morris M. J. Effects of vagal and splanchnic section on food intake, weight, serum leptin and hypothalamic neuropeptide Y in rat. Autonomic Neuroscience. 2001;92(1-2):28–36. doi:10.1016/s1566-0702(01)00311-3. [PubMed] [CrossRef] [Google Scholar]
32. Remely M., Aumueller E., Merold C., et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2014;537(1):85–92. doi:10.1016/j.gene.2013.11.081. [PubMed] [CrossRef] [Google Scholar]
33. Vrieze A., Holleman F., Zoetendal E. G., de Vos W. M., Hoekstra J. B., Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010;53(4):606–613. doi:10.1007/s00125-010-1662-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
34. Wang L., Li P., Tang Z., Yan X., Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Scientific Reports. 2016;6(1) doi:10.1038/srep33251.33251 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
35. Zhao L., Chen Y., Xia F., et al. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Frontiers in Endocrinology. 2018;9:p. 233. doi:10.3389/fendo.2018.00233. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Busetto L., Bettini S., Makaronidis J., Roberts C. A., Halford J. C. G., Batterham R. L. Mechanisms of weight regain. European Journal of Internal Medicine. 2021;93:3–7. doi:10.1016/j.ejim.2021.01.002. [PubMed] [CrossRef] [Google Scholar]
37. Schwartz M. W., Woods S. C., Porte D., Seeley R. J., Baskin D. G. Central nervous system control of food intake. Nature. 2000;404(6778):661–671. doi:10.1038/35007534. [PubMed] [CrossRef] [Google Scholar]
38. Sumithran P., Prendergast L. A., Delbridge E., et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011;365(17):1597–1604. doi:10.1056/nejmoa1105816. [PubMed] [CrossRef] [Google Scholar]
39. Chearskul S., Delbridge E., Shulkes A., Proietto J., Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. The American Journal of Clinical Nutrition. 2008;87(5):1238–1246. doi:10.1093/ajcn/87.5.1238. [PubMed] [CrossRef] [Google Scholar]
40. Cummings D. E., Weigle D. S., Frayo R. S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine. 2002;346(21):1623–1630. doi:10.1056/NEJMoa012908. [PubMed] [CrossRef] [Google Scholar]
41. Iepsen E. W., Lundgren J., Dirksen C., et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. International Journal of Obesity. 2015;39(5):834–841. doi:10.1038/ijo.2014.177. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167–172. doi:10.1016/s0140-6736(97)11509-4. [PubMed] [CrossRef] [Google Scholar]
43. Fothergill E., Guo J., Howard L., et al. Persistent metabolic adaptation 6 years after the Biggest Loser competition. Obesity. 2016;24(8):p. 001612. doi:10.1002/oby.21538. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
44. Baggio L. L., Drucker D. J. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. Journal of Clinical Investigation. 2014;124(10):4223–4226. doi:10.1172/JCI78371. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
45. Berthoud H.-R. Multiple neural systems controlling food intake and body weight. Neuroscience and Biobehavioral Reviews. 2002;26(4):393–428. doi:10.1016/s0149-7634(02)00014-3. [PubMed] [CrossRef] [Google Scholar]
46. Holst J. J. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006. [PubMed] [CrossRef] [Google Scholar]
47. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. The Journal of Comparative Neurology. 1999;403(2):261–280. doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5. [PubMed] [CrossRef] [Google Scholar]
48. Kappe C., Tracy L. M., Patrone C., Iverfeldt K., Sjöholm Å. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. Journal ofNeuroinflammation. 2012;9(1):p. 766. doi:10.1186/1742-2094-9-276. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Parker H. E., Reimann F., Gribble F. M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Reviews in Molecular Medicine. 2010;12(e1) doi:10.1017/s146239940900132x. [PubMed] [CrossRef] [Google Scholar]
50. Secher A., Jelsing J., Baquero A. F., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014;124(10):4473–4488. doi:10.1172/JCI75276. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
51. Wadden T. A., Bailey T. S., Billings L. K., et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Wadden T. A., Hollander P., Klein S., et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2013;37(11):1443–1451. doi:10.1038/ijo.2013.120. [PubMed] [CrossRef] [Google Scholar]
53. Rubino D., Abrahamsson N., Davies M., et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, the Journal of the American Medical Association. 2021;325(14):p. 1414. doi:10.1001/jama.2021.3224. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Le Roux C. W., Astrup A., Fujioka K., et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. 2017;389(10077):1399–1409. doi:10.1016/S0140-6736(17)30069-7. [PubMed] [CrossRef] [Google Scholar]
